Pharma Focus Asia
KP - Choose our fully recyclable blister films

Eli Lilly and Company Launched New Rapid Acting Insulin Lyumjev™

Lyumjev™, a new and innovative rapid acting insulin ranging from 100 units/mL and 200 units/mL was launched by Eli Lilly and Company to enhance glycemic control in diabetic patients of type 1 & 2.

Lyumjev is a novel formulation of insulin lispro, designed to speed the absorption of insulin into the blood stream and reduce A1C levels. This new rapid-acting insulin, Lyumjev manages the blood sugar levels in diabetic adult patients after meals similar to the working of natural working of insulin after meals in people without diabetes.

With the new technological advancements made in glucose monitoring, patients can now easily see the blood glucose spikes that happen naturally after a meal. Lyumjev™, serves as a new treatment option for patients with diabetes to help them control post-meal blood sugar levels.

Lyumjev™, fast acting insulin was approved by US Food and Drug Administration (FDA) based on the Phase 3 studies PRONTO-T1D and PRONTO-T2D,which were randomised, active controlled, treat-to-target comparisons of Lyumjev and Humalog® (insulin lispro injection, 100 units/mL) in adults with type 1 and type 2 diabetes, respectively.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024